What Is Propanc Biopharma, Inc. (PPCB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Propanc Biopharma, Inc.'s intrinsic value is estimated at $1.78, suggesting a +9.1% average upside from the current price of $1.63. While 4 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: Dynamic NAV targets $3.82 (+134.3%), versus Markov DDM at $0.22 (-86.8%). This +221.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About PPCB?
7 of 13 models are currently active for PPCB. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates PPCB's intrinsic value at $0.45, implying -72.3% downside from the current price. See which stocks rank higher →
How Does PPCB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PPCB ranks #364 by Quality of Company score. CirclFi's QOC score of 3.6/10 evaluates 32 fundamental signals. A score of 3.6 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Propanc Biopharma, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating PPCB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is PPCB a Value Trap?
CirclFi's Value Trap algorithm assigns PPCB a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Propanc Biopharma, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Propanc Biopharma, Inc.'s fundamental quality profile registers 3.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +221.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PPCB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PPCB's 7 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad